Viewing data from:

RAMELTEON

ANDA

RAMELTEON | A091610 | ACTAVIS LABORATORIES FL INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: ROZEREM(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Ramelteon (2023)

Total Spending

$25.0M

Total Claims

179,751

Beneficiaries

52,872

Avg Cost/Unit

$3.83

Spending Trend

$8.9M(2019)→$18.5M(2020)→$23.2M(2021)→$21.9M(2022)→$25.0M(2023)

YoY Change:-3.2%

5yr CAGR:-14.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain7 active DMFs

7 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVRAMELTEON

DMF 228822009

MSN LABORATORIES PRIVATE LTDRAMELTEON

DMF 315062017

SS PHARMA LLCRAMELTEON

DMF 324442018

ENALTEC LABS PRIVATE LTDRAMELTEON

DMF 336012019

ZHEJIANG AUSUN PHARMACEUTICAL CO LTDRAMELTEON

DMF 337192019

BIOPHORE INDIA PHARMACEUTICALS PVT LTDRAMELTEON

DMF 344142019

APITORIA PHARMA PRIVATE LTDRAMELTEON

DMF 348992020

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 8MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 19, 2015

No patent or exclusivity listings for this strength.